

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2023

Acrivon Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-41551
(Commission
File Number)

82-5125532
(IRS Employer
Identification No.)

480 Arsenal Way, Suite 100
Watertown, Massachusetts
(Address of Principal Executive Offices)

02472

(Zip Code)

(617) 207-8979

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Common Stock, \$0.001 par value

ACRV

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 22, 2023, Acrivon Therapeutics, Inc. (the "Company") held its 2023 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, a quorum of 17,880,383 shares of the Company's common stock, or 81.55% of the outstanding shares of common stock entitled to vote as of the record date of April 24, 2023, were present or represented by proxy.

Three items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.

Proposal One: Election of Michael Tomsicek, M.B.A. as a Class I Director

Michael Tomsicek was elected to serve as a Class I director to hold office until the Company's 2026 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows:

| | For | Withheld | Broker Non-Votes |
|--------------------------|------------|-----------------|-------------------------|
| Michael Tomsicek, M.B.A. | 17,527,002 | 226,168 | 127,213 |

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote:

| | For | Against | Abstain | Broker Non-Votes |
|--|------------|----------------|----------------|-------------------------|
| | 17,879,658 | 725 | 0 | - |

Proposal Three: Election of Charles Baum, M.D., Ph.D. as a Class I Director

Charles Baum was elected to serve as a Class I director to hold office until the Company's 2026 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows:

| | For | Withheld | Broker Non-Votes |
|---------------------------|------------|-----------------|-------------------------|
| Charles Baum, M.D., Ph.D. | 17,660,794 | 91,113 | 128,476 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Acrivon Therapeutics, Inc.

Date: June 22, 2023

By: /s/ Peter Blume-Jensen
Peter Blume-Jensen, M.D., Ph.D.
Chief Executive Officer and President

